Product image of Monlunca (Lutetium (177lu) Chloride) supplied by GNH India

Monlunca

Active Ingredient:
Lutetium (177lu) Chloride
Origin:
EU

Monlunca (Lutetium (177lu) Chloride)

Lutetium-177 chloride, the active ingredient in Monlunca, is a radiopharmaceutical presented as a sterile solution for intravenous use. It delivers targeted radiation to malignant cells in patients with specific oncologic conditions.
GNH India supplies Monlunca as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Monrol Europe Srl

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Monlunca is employed in radionuclide therapy for tumors that express specific molecular targets.

  • Gastroenteropancreatic neuroendocrine tumors: provides localized radiation to reduce tumor burden and control disease progression.
  • Metastatic neuroendocrine tumors: delivers beta‑particle emission to shrink metastatic lesions and alleviate symptoms.
  • PSMA‑positive metastatic prostate cancer: targets prostate‑specific membrane antigen to deliver cytotoxic radiation to cancer cells.

How It Works

  • Lutetium-177 chloride emits beta particles that travel a short distance in tissue, causing DNA double‑strand breaks and localized cell death. The radionuclide is conjugated to a targeting molecule (e.g., peptide or antibody) that binds selectively to receptors or antigens on tumor cells, concentrating the radiation within the malignant tissue while sparing surrounding healthy structures.

Side Effects

Adverse reactions are related to radiation exposure and the carrier molecule used for targeting.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset after administration.
  • Fatigue: transient tiredness lasting days to weeks.
  • Transient hematologic changes: temporary reduction in blood cell counts.
  • Mild renal function changes: slight increase in serum creatinine.
  • Injection site discomfort: brief pain or irritation at the infusion site.

Serious or Rare Side Effects

  • Severe bone marrow suppression: prolonged pancytopenia requiring medical intervention.
  • Renal toxicity: significant decline in kidney function.
  • Hepatotoxicity: elevated liver enzymes indicating liver injury.
  • Allergic reactions: anaphylaxis or severe hypersensitivity to the carrier molecule.

Precautions & Warnings

Prior to therapy, patients should be evaluated for organ function and potential contraindications.

  • Renal assessment: ensure adequate kidney function before dosing.
  • Hematologic monitoring: baseline blood counts required to detect marrow suppression.
  • Pregnancy avoidance: women of childbearing potential must use effective contraception.
  • Radiation safety: follow institutional protocols to protect staff and family members.
  • Drug interactions: review concurrent therapies that may exacerbate hematologic or renal effects.

Store at ambient temperature: keep in original container, protect from light and moisture, and avoid freezing.

Avoid Interactions

Lutetium‑177 chloride may interact with drugs that affect blood cell production or renal clearance.

Major Interactions (Avoid)

  • Myelosuppressive chemotherapy: concurrent use can cause severe bone marrow failure.
  • Nephrotoxic agents (e.g., high‑dose cisplatin): may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: monitor for increased bleeding risk due to thrombocytopenia.
  • ACE inhibitors or ARBs: watch renal function closely.
  • Immunosuppressants: assess infection risk as leukopenia may be compounded.

Frequently Asked Questions

Monlunca is a radiopharmaceutical that delivers targeted beta‑particle radiation to tumors expressing specific molecular markers, such as neuroendocrine tumors and PSMA‑positive prostate cancer. It is used under specialist supervision to reduce tumor size, control disease spread, and alleviate related symptoms.

Lutetium‑177 chloride emits beta particles that travel only a few millimeters, causing DNA damage and cell death in the tumor cells to which it is directed. The radionuclide is attached to a targeting vector that binds selectively to receptors on cancer cells, concentrating the radiation within the malignant tissue while limiting exposure to healthy organs.

The dose of Monlunca is individualized by the treating physician based on the patient’s disease characteristics, body weight, renal function, and prior therapies. The prescribing oncologist determines the appropriate activity (megabecquerels) and schedule for each treatment cycle.

Monlunca is contraindicated in pregnancy because the radiation can harm the developing fetus. Women of childbearing potential should use effective contraception before and after treatment. Breastfeeding is not recommended, as the drug may be excreted in milk and could expose the infant to radiation.

To request Monlunca, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Monlunca’s active ingredient, Lutetium‑177 chloride, offers a balance of beta‑particle energy and half‑life that allows effective tumor irradiation with manageable safety profile. Compared with Yttrium‑90 based agents, Lutetium‑177 provides deeper tissue penetration with lower renal toxicity, making it suitable for a broader range of tumor sizes and locations.

Monlunca should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and freezing. Follow all local radiation safety regulations when handling and disposing of the material.

Monlunca is administered intravenously by a qualified healthcare professional in a controlled clinical setting. The infusion is typically performed over a short period, and patients are monitored for immediate reactions and vital signs during and after the procedure.

The most serious risks include severe bone marrow suppression leading to pancytopenia, significant renal toxicity, and rare allergic reactions. Patients should be closely monitored for blood count changes, kidney function, and any signs of hypersensitivity throughout treatment.

Monlunca should not be given to patients with severe renal impairment, uncontrolled bone marrow failure, known hypersensitivity to the carrier molecule, or pregnant or breastfeeding women. Additionally, individuals receiving other myelosuppressive therapies should be evaluated carefully before treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lutetium (177lu) Chloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT